Subscribe to news

Financial Highlights

INTERNATIONAL FINANCIAL REPORTING STANDARDS (IFRS)

1H 2018 consolidated results (audited)

'000 RUB 6mo 2018 6mo 2017 % change, y-o-y
Revenue from products and services:      
Isolation, crypreservation and personal storage of cord blood stеm cells 122,472 111,286 10.1%
Neovasculgen® 3,262 9,945 -67.2%
SPRS-therapy® 20,345 20,294 0.3%
Genetico®center & lab (genetic testing and counselling, Reprobank®) 146,886 81,947 79.2%
Other revenue 227 3,481 -93.5%
Total revenue 293,192 226,953 29.2%
Wages, salaries, other benefits and payroll taxes (109,419) (113,118) -3.3%
Rental fee (21,712) (16,083) 35.0%
Supplies and reagents (49,246) (35,549) 38.5%
Services of third-party organizations (contractors) (19,931) (31,422) -36.6%
Consulting and legal services (8,272) (15,119) -45.3%
Advertising costs (25,819) (14,486) 78.2%
R&D costs (2,298) (3,300) -30.4%
Transportation, Travel and Representation expenses (12,757) (16,664) -23.4%
Bad debt recovery/ (expense) (6,247) (6,790) -8.0%
Telecommunications services, software and maintenance (4,991) (5,307) -6.0%
Tax expenses (711) (660) 7.7%
Maintenance of cryogenic equipment (656) (435) 50.8%
Audit fees (700) (240) 191.7%
Other operating expenses  (8,380) (13,060) -35.8%
Operating expenses before depreciation & amortization (271,285) (272,233) -0.4%
OIBDA 22,053 (25,280) n/a
OIBDA margin, % 7.5% n/a n/a
     Depreciation & amortization (25,146) (10,467) 140.2%
Total operating expenses  (296,285) (282,700) 4.8%
Operating profit / (loss) (3,093) (55,747) -94.5%
Operating margin, % n/a n/a n/a
Gain / (loss) from associates 0 (328) -100%
       
   Other income/ (loss) - net, incl. 30,440 (2,019) n/a
     Net interest expense (interest income + interest expense) (13,833) (7,142) 93.7%
     Other non-operating income / (loss) - net, incl. 48,082 4,883 by 8.8 times
     Foreign exchange gain / (loss), net (3809) 240 n/a
Profit / (loss) before income tax 27,347 (58,094) n/a
     Income tax  6,422 1,878 242.0%
Profit/ (loss) for the period (net profit/ (loss)) 33,769 (56,216) n/a
Net margin, % 11.5% n/a n/a
Total comprehensive income / (loss) for the period, net of tax 33,769 (56,216) n/a

 

 Press-release on 6mo 2018 IFRS results 


1H 2018 IFRS Revenue Breakdown

revenue2017


2017 consolidated results (audited)

'000 RUB 2017 2016 % change, y-o-y
Revenue from products and services:      
Isolation, crypreservation and personal storage of cord blood stеm cells 222,714 203,040 9.7%
Neovasculgen® 25,409 7,011 262.4%
SPRS-therapy® 35,150 36,688 -4.2%
Genetico®center & lab (genetic testing and counselling, Reprobank®) 210,964 141,925 48.6%
Revenue from R&D - 811 n/a
Other revenue 204 881 -76.8%
Total revenue 494,441 390,356 26.7%
Wages, salaries, other benefits and payroll taxes (200,645) (132,656) 51.3%
Rental fee (38,187) (34,667) 10.2%
Supplies and reagents (84,248) (60,309) 39,7%
Services of third-party organizations (contractors) (42,720) (54,482) -21,6%
Consulting and legal services (18,174) (77,331) -76.5%
Advertising costs (46,143) (52,559) -12.2%
R&D costs (4,906) (36,908) -86.7%
Transportation, Travel and Representation expenses (28,294) (17,865) 58.4%
Bad debt recovery/ (expense) (24,808) (10,799) 129.7%
Telecommunications services, software and maintenance (10,644) (9,390) 13.4%
Tax expenses (1,866) (1,613) 15.7%
Maintenance of cryogenic equipment (1,011) (2,268) -55.4%
Audit fees (1,750) (911) 92.5%
Other operating expenses  (8,728) (18,277) -52.2%
Operating expenses before depreciation & amortization (512,124) (510,035) 0.4%
OIBDA (17,683) (119,679) -85.2%
OIBDA margin, % n/a n/a n/a
     Depreciation & amortization (40,460) (23,992) 68.6%
Total operating expenses  (552,584) (534,027) 3.5%
Operating profit / (loss) (58,143) (143,671) -59.5%
Operating margin, % n/a n/a n/a
Gain / (loss) from associates (396) (460) -13.9%
       
   Other income/ (loss) - net, incl. (68,640) (5,583) by 12.3 times
     Net interest expense (interest income + interest expense) (20,572) (23,165) -11.2%
     Other non-operating income / (loss) - net, incl. (47,743) 20,037 n/a
          Gain / (loss) from sale of securities (53,492) (4,519) by 11.8 times
          Gain / (loss) from revaluation of financial instruments held for trading (purchased quoted securities) 238 (12,064) n/a
     Foreign exchange gain / (loss), net (325) (2,455) -86.8%
Profit / (loss) before income tax (127,179) (149,714) -15.1%
     Income tax  17,204 18,746 -8.2%
Profit/ (loss) for the period (net profit/ (loss)) (109,975) (130,968) -16.0%
Net margin, % n/a n/a n/a
Other comprehensive income, net of tax - - n/a
Total comprehensive income / (loss) for the period, net of tax (109,975) (130,968) -16.0%

 

 Press-release on 2017 IFRS results 


2017 IFRS Revenue Breakdown

revenue2017